Inventor · disambiguated record
André Schrattenholz
Also filed as: SCHRATTENHOLZ ANDRE · SCHRATTENHOLZ ANDRÉ
15 granted patents·16 pending applications·27 citations·filing 2001–2020
89Inventor score
Top patents by PatentIndex Score
31 records- 0182US10813978B2Method of effecting neuroprotection using soluble neuregulin isoformsMIND NRG SARL·Filed 2019·Granted Oct 27, 2020·1 cites·11 claims
- 0282US7732148B2Annexin A3 for prostate cancer diagnosisPROTEOSYS AG·Filed 2006·Granted Jun 8, 2010·10 cites·8 claims
- 0381US8039464B2Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseasesPROTEOSYS AG·Filed 2005·Granted Oct 18, 2011·5 cites·7 claims
- 0479US7919582B2Neuregulin-β isoformMIND NRG SA·Filed 2009·Granted Apr 5, 2011·4 cites·6 claims
- 0576US10350269B2Method of effecting neuroprotection using soluble Neuregulin isoformsMIND NRG SARL·Filed 2016·Granted Jul 16, 2019·1 cites·11 claims
- 0676US8012697B2Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinomaPROTEOSYS AG·Filed 2007·Granted Sep 6, 2011·3 cites·18 claims
- 0774US12251423B2Method of effecting neuroprotection using soluble neuregulin isoformsMIND NRG SARL·Filed 2020·Granted Mar 18, 2025·0 cites·11 claims
- 0873US7538197B2Use of neuregulin-β as an indicator and/or targetPROTEOSYS AG·Filed 2001·Granted May 26, 2009·2 cites·5 claims
- 0973US2021128687A1Method of effecting neuroprotection using soluble neuregulin isoformsMIND NRG SARL·Filed 2020·Application pending·0 cites
- 1068US7998970B2Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disordersPROTEOSYS AG·Filed 2005·Granted Aug 16, 2011·1 cites·11 claims
- 1166US2010256066A1Active soluble post-translationally modified neuregulin isoformsPROTEOSYS AG·Filed 2008·Application pending·0 cites
- 1264US2014243269A1Method of effecting neuroprotection using soluble neuregulin isoformsPROTEOSYS AG·Filed 2014·Application pending·0 cites
- 1364US2014323408A1Method of inhibiting dopaminergic cell deathPROTEOSYS AG·Filed 2014·Application pending·0 cites
- 1464US2014243270A1Pharmaceutical composition containing neuregulin isoformsPROTEOSYS AG·Filed 2014·Application pending·0 cites
- 1561US2015239948A1Active soluble post-translationally modified neuregulin isoformsMIND NRG SA·Filed 2014·Application pending·0 cites
- 1655US8377648B2Autoimmune regulation of prostate cancer by annexin A3PROTEOSYS AG·Filed 2008·Granted Feb 19, 2013·0 cites·16 claims
- 1752US8546086B2Use of neuregulin-β as an indicator and/or targetSCHRATTENHOLZ ANDRE·Filed 2011·Granted Oct 1, 2013·0 cites·4 claims
- 1850US2011143366A1Protein biomarkers for in vitro testing of developmental toxicity and enbryotoxicity of chemical substancesPROTEOSYS AG·Filed 2009·Application pending·0 cites
- 1950US2014271922A1Pirenzepine as an agent in cancer treatmentPROTEOSYS AG·Filed 2013·Application pending·0 cites
- 2049US8466144B2Muscarinic antagonists with parp and sir modulating activity as cytoprotective agentsSCHRATTENHOLZ ANDRE·Filed 2005·Granted Jun 18, 2013·0 cites·7 claims
- 2149US2007298448A1Enrichment of Enzymatic Cleavage ProductsPROTEOSYS AG·Filed 2004·Application pending·0 cites
- 2249US2010247688A1Pirenzepine and derivatives thereof as anti-amyloid agentsPFEIFER ANDREA·Filed 2008·Application pending·0 cites
- 2346US2015080302A1Neuregulin isoforms, neuregulin polypeptides and uses thereofMIND NRG SA·Filed 2014·Application pending·0 cites
- 2442US2013072437A1Neuregulin isoforms,neuregulin polypeptides and uses thereofBAUSSANT THIERRY·Filed 2011·Application pending·0 cites
- 2539US2011098234A1Breast cancer proteinsCAHILL MICHAEL·Filed 2005·Application pending·0 cites
- 2638US2009061461A1Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Therapeutic TargetCAHILL MICHAEL·Filed 2006·Application pending·0 cites
- 2737US2011294791A1Pirenzepine as an agent in cancer treatmentSCHRATTENHOLZ ANDRE·Filed 2010·Application pending·0 cites
- 2835US8409812B2Annexin A3 for cancer diagnosisCAHILL MICHAEL·Filed 2010·Granted Apr 2, 2013·0 cites·20 claims
- 2935US7824923B2Neuregulin-β isoforms associated with neuronal processesPROTEOSYS AG·Filed 2002·Granted Nov 2, 2010·0 cites·2 claims
- 3034US2011263574A1Pirenzepine as otoprotective agentPROTEOSYS AG·Filed 2010·Application pending·0 cites
- 3133US7759068B2Use of substances for treating tumorsPROTEOSYS AG·Filed 2003·Granted Jul 20, 2010·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when André Schrattenholz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →